Stockreport

Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics, Inc.  (SLNO) 
Last soleno therapeutics, inc. earnings: 5/13 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.soleno.life/investor-overview
PDF First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3 Program for DCCR Planned Submission of a New D [Read more]